Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?

Journal Submission Sample Work

Choosing the right journal plays a pivotal role in determining the visibility, credibility, and scholarly impact of a research manuscript. This journal submission report evaluates potential publication venues for the manuscript titled “Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?” Journals were selected based on their relevance to cancer etiology research, methodological rigor, and use of molecular tumor classification, along with considerations of scope, indexing coverage, impact metrics, and peer-review efficiency. The report offers a comparative overview to guide authors toward an informed and strategically aligned submission choice.

A methodological question in cancer epidemiology

Many cancers are no longer treated as single diseases. Breast tumours, for example, are routinely classified by hormone-receptor and HER2 status, and epidemiologists increasingly ask whether a risk factor is associated more strongly with one molecular subtype than another. This is the study of etiologic heterogeneity. It promises sharper insight into causation, but it raises difficult interpretive questions: tumour markers are measured after disease develops, marker data are often incomplete or misclassified, and an exposure might influence which subtype develops rather than whether cancer develops at all. Distinguishing these possibilities draws on causal inference and, in some designs, mediation analysis.

The manuscript behind this journal submission report asks directly: Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors? Its keywords — etiologic heterogeneity, molecular markers, tumour subtyping, causal inference, mediation analysis and exposure–disease association — mark it as a methodological and conceptual paper. That affects journal choice sharply, because many oncology journals do not publish methods papers without new data.

Why the report confines itself to three cancer-research journals

The report recommends three titles that publish methodological work alongside empirical studies:

  1. Cancer Epidemiology, Biomarkers & Prevention (American Association for Cancer Research) is described as publishing original research, methodological papers and conceptual articles on etiologic mechanisms and the use of molecular markers. Its examples include a population-based study of risk-factor differences across breast cancer molecular subtypes and a paper on biomarker discovery for heterogeneous diseases.
  2. Cancer Research (AACR), the association's flagship journal, is presented in the supporting table as suited to conceptual and analytical articles on the biological and methodological implications of tumour classification. Its examples are a 2017 analysis showing subtype heterogeneity in breast cancer risk factors and a 2018 pooled analysis of nine cohorts by tumour molecular subtype.
  3. JNCI: Journal of the National Cancer Institute (Oxford University Press) is recommended for its focus on cancer etiology and methodology; examples include a review of breast cancer heterogeneity from an etiological perspective and a meta-analysis of risk factors for triple-negative breast cancer.

Every example concerns breast cancer subtypes, the setting in which etiologic heterogeneity has been studied most, so they show convincingly that each journal has engaged with the problem.

Open-access licence choices and other comparator details

The comparator, reproduced here as reported in the sample, shows one feature that many reports omit: the article processing charge depends on the licence chosen. Figures of this kind change annually and should be confirmed before submission.

  • Cancer Epidemiology, Biomarkers & Prevention: impact factor 3.4; review 4–6 weeks; acceptance about 25%; APC USD 4,000 under CC BY-NC-ND or USD 5,000 under CC BY; 4,000 words, six display items, up to 100 references.
  • Cancer Research: impact factor 16.6; review 3–5 weeks; APC USD 7,000 (CC BY-NC-ND) or USD 8,000 (CC BY); 5,000 words, eight display items, up to 50 references.
  • JNCI: impact factor 7.2; review 4–6 weeks; acceptance below 10%; APC from USD 4,000 to USD 5,000 or more depending on licence; 3,000 words or fewer, figures as needed, no reference limit.

The licence question matters because some funders require CC BY, the most permissive licence, which is also the more expensive option at both AACR journals as reported.

Selectivity is the other clear divide. The reported acceptance rate for JNCI is below 10% and its rejection rate above 90%, against roughly 25% acceptance at Cancer Epidemiology, Biomarkers & Prevention; no rate is given for Cancer Research. Indexing is not a differentiator here, since all three are covered by PubMed/MEDLINE, Scopus and Web of Science, as the appendix confirms.

Fitting a conceptual argument to each journal's format

A methodological paper on etiologic heterogeneity typically needs worked examples, simulation results or directed acyclic graphs to make its case, so word and figure limits are decisive. A 3,000-word ceiling at JNCI would suit a tightly argued commentary; Cancer Epidemiology, Biomarkers & Prevention, which explicitly lists methodological and conceptual papers among its article types and allows up to 100 references, gives room for a fuller treatment. The report's appendix recommends conceptual and methodological articles, narrative or systematic reviews, commentaries and perspectives as the most suitable formats.

Before submission, the analytical claims deserve independent scrutiny: statements about bias from marker misclassification or about mediation assumptions will be examined closely by epidemiologist reviewers. Pubrica's biostatistics team and pre-submission peer review can test those arguments, and the journal submission service manages the final package.

Questions about this sample

What is etiologic heterogeneity in cancer research?

It describes the situation in which risk factors differ in their association with distinct tumour subtypes, such as breast cancers classified by hormone-receptor status. Studying it can clarify causal pathways, but interpretation is complicated because markers are measured after diagnosis, may be missing or misclassified, and may reflect how a tumour develops rather than why it occurs.

Why is Cancer Epidemiology, Biomarkers & Prevention a natural first choice?

The report notes that it publishes methodological and conceptual papers as well as original research, with an emphasis on biomarker-based tumour classification. As reported in the sample, it allows up to 100 references and has an acceptance rate of about 25 percent, making it more accessible than JNCI for a conceptual manuscript.

Why do the article processing charges in this report vary by licence?

The AACR journals charge less for a CC BY-NC-ND licence than for CC BY, which permits commercial reuse. As reported in the sample, the difference is USD 1,000 at both. Authors whose funders mandate CC BY should budget for the higher charge and confirm current prices before submitting.

Are all the example articles in the report about breast cancer?

Yes. Each journal's supporting examples examine risk factors or heterogeneity across breast cancer subtypes. This reflects the research record, as breast cancer is where subtype-specific epidemiology is most developed. The manuscript's argument may apply to other tumours, which authors could emphasise in a cover letter.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.